NBS, Neostem, Inc.NBS is an international biopharmaceutical company with adult stem cell operations in the U.S., a network of adult stem cell therapeutic providers in China as well as a 51% ownership interest in a profitable Chinese generic pharmaceutical manufacturing company.
NBS is focused on accelerating the development of proprietary cellular therapies and becoming a single source for collection, storage, manufacturing, therapeutic development and transportation of cells for cell based medicine and regenerative science globally.
NBS also has licensed various cellular therapy technologies, including worldwide exclusive licenses to a wound healing technology and to VSEL™ Technology which uses very small embryonic-like stem cells, which are adult stem cells that have been shown to have several physical characteristics that are generally found in embryonic stem cells.
NBS reported unaudited results for 2010. Highlights Include:
- Revenues for the year ended December 31, 2010 were $69.8 million compared with $11.6 million for 2009. 2010 was the first full year that results for the Company's 51% owned subsidiary, Suzhou Erye Pharmaceutical Co. Ltd. ("Erye"), were included in the Company's results.
- For the year ended December 31, 2010, revenues increased 13% over the 2009 pro forma revenue of $61.7 million.
- Cash and cash equivalents at December 31, 2010 were $15.6 million.
No comments:
Post a Comment